Recent Updates
Recently added Catalysts
EOLS Positive Sentiment

Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality

Wednesday, July 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Evolus, Inc. has announced a partnership with IBSA to exclusively develop and commercialize Profhilo® in the United States. This injectable is recognized as a market leader in Europe for improving skin quality. The collaboration aims to enhance Evolus's aesthetic product offerings and expand its market reach in the U.S.
Price reaction · baseline $6.94 (2026-07-07 close) · hit pre-market · clean, no other EOLS news in the window
day 0 close · peak
-2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Evolus expands its product portfolio with a leading injectable.
  • Partnership with IBSA enhances market presence in the U.S.
  • Profhilo® has strong brand recognition in Europe.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~37 mo
Minimal dilution risk
Lead asset
PrabotulinumtoxinA-Xvfs
Phase 2 · Glabellar Frown Lines

Full Press Release Details

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and commercialize Profhilo® in the United States. Profhilo® is the market-leading injectable in Europe for skin quality, with global brand recognition and availability in m

Frequently Asked Questions

What is the focus of Evolus, Inc.?

Evolus, Inc. focuses on building an aesthetic portfolio of consumer brands.

What is Profhilo® known for?

Profhilo® is recognized as a market-leading injectable for skin quality in Europe.

Who is Evolus partnering with for Profhilo®?

Evolus has partnered with IBSA, a Swiss multinational pharmaceutical company.

What is the goal of the Evolus and IBSA partnership?

The partnership aims to develop and commercialize Profhilo® in the United States.

ShareAdd on Google
Tags: EOLS Viatris Investor Conferences Healthcare Evolus IBSA Profhilo injectable skin quality
Last updated: Jul 8, 2026

Biotech snapshot

Cash runway
$45M liquidity · $1M/mo burn
~37 mo
Minimal dilution risk
Lead asset
PrabotulinumtoxinA-XvfsPhase 2
Glabellar Frown Lines →